Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap

Trends in Cancer

Volumn 3, Issue 2, 2017, Pages 149-160

  Eruslanov, Evgeniy B ^a   Singhal, Sunil ^a,c   Albelda, Steven M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; EXTRACELLULAR TRAP; GENETIC HETEROGENEITY; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; MALIGNANT NEOPLASM; MYELOID-DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; NEOPLASM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS; NEUTROPHIL INFILTRATION; NEUTROPHILS; TUMOR MICROENVIRONMENT;

EID: 85009774269     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.12.006     Document Type: Review

References (98)

1. 1 Carus, A., et al. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer 81 (2013), 130–137.
2. 2 Ilie, M., et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 118 (2012), 1726–1737.
3. 3 Jensen, H.K., et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27 (2009), 4709–4717.
4. 4 Jensen, T.O., et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118 (2012), 2476–2485.
5. 5 Brandau, S., The dichotomy of neutrophil granulocytes in cancer. Semin. Cancer Biol. 23 (2013), 139–140.
6. 6 Sionov, R.V., et al. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron. 8 (2015), 125–158.
7. 7 Granot, Z., Jablonska, J., Distinct functions of neutrophil in cancer and its regulation. Mediators Inflamm., 2015, 2015, 701067.
8. 8 Moses, K., Brandau, S., Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin. Immunol. 28 (2016), 187–196.
9. 9 Coffelt, S.B., et al. Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16 (2016), 431–446.
10. 10 Schreiber, R.D., et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
11. 11 Fridlender, Z.G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16 (2009), 183–194.
12. 12 Brandau, S., et al. Protumor and antitumor functions of neutrophil granulocytes. Semin. Immunopathol. 35 (2013), 163–176.
13. 13 Piccard, H., et al. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit. Rev. Oncol. Hematol. 82 (2012), 296–309.
14. 14 Di Carlo, E., et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97 (2001), 339–345.
15. 15 Dallegri, F., Ottonello, L., Neutrophil – mediated cytotoxicity against tumour cells: state of art. Arch. Immunol. Ther. Exp. (Warsz) 40 (1992), 39–42.
16. 16 van Egmond, M., Bakema, J.E., Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin. Cancer Biol. 23 (2013), 190–199.
17. 17 Mantovani, A., et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11 (2011), 519–531.
18. 18 Kousis, P.C., et al. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 67 (2007), 10501–10510.
19. 19 Suttmann, H., et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66 (2006), 8250–8257.
20. 20 Murray, P.J., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
21. 21 Bronte, V., et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun., 7, 2016, 12150.
22. 22 Sagiv, J.Y., et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10 (2015), 562–573.
23. 23 Fridlender, Z.G., et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One, 7, 2012, e31524.
24. 24 Youn, J.I., et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91 (2012), 167–181.
25. 25 Brandau, S., et al. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. Semin. Cancer Biol. 23 (2013), 171–182.
26. 26 Pillay, J., et al. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell Mol. Life Sci. 70 (2013), 3813–3827.
27. 27 Condamine, T., et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1 (2016), 1–15.
28. 28 Arina, A., et al. Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J. Immunol. 192 (2014), 1286–1293.
29. 29 Schmidt, K., et al. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood 121 (2013), 1740–1748.
30. 30 Sun, Z., Yang, P., Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 5 (2004), 182–190.
31. 31 Gregory, A.D., Houghton, A.M., Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 71 (2011), 2411–2416.
32. 32 Felix, K., Gaida, M.M., Neutrophil-derived proteases in the microenvironment of pancreatic cancer – active players in tumor progression. Int. J. Biol. Sci. 12 (2016), 302–313.
33. 33 Houghton, A.M., et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat. Med. 16 (2010), 219–223.
34. 34 Mittendorf, E.A., et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 72 (2012), 3153–3162.
35. 35 Chawla, A., et al. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol. Immunother. 65 (2016), 741–751.
36. 36 Kisker, O., et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 61 (2001), 7298–7304.
37. 37 Rodriguez, P.C., et al. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109 (2007), 1568–1573.
38. 38 Munder, M., et al. Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion. PLoS One, 8, 2013, e63521.
39. 39 Feldmeyer, N., et al. Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. Int. Immunol. 24 (2012), 303–313.
40. 40 Feun, L., et al. Arginine deprivation as a targeted therapy for cancer. Curr. Pharm. Des. 14 (2008), 1049–1057.
41. 41 Ensor, C.M., et al. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 62 (2002), 5443–5450.
42. 42 Brinkmann, V., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004), 1532–1535.
43. 43 Cools-Lartigue, J., Neutrophil extracellular traps in cancer progression. Cell Mol. Life Sci. 71 (2014), 4179–4194.
44. 44 Saffarzadeh, M., et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One, 7, 2012, e32366.
45. 45 Clark, R.A., Szot, S., The myeloperoxidase-hydrogen peroxide-halide system as effector of neutrophil-mediated tumor cell cytotoxicity. J. Immunol. 126 (1981), 1295–1301.
46. 46 Skrzeczynska-Moncznik, J., Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cells: implication for psoriasis. J. Immunol. 189 (2012), 1611–1617.
47. 47 Tillack, K., et al. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J. Immunol. 188 (2012), 3150–3159.
48. 48 Mak, I.W., et al. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6 (2014), 114–118.
49. 49 Pettit, S.J., et al. Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br. J. Cancer 82 (2000), 1900–1906.
50. 50 Lipinski, K.A., et al. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2 (2016), 49–63.
51. 51 Cheon, D.J., Orsulic, S., Mouse models of cancer. Annu. Rev. Pathol 6 (2011), 95–119.
52. 52 Merlo, L.M., et al. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6 (2006), 924–935.
53. 53 Bald, T., et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507 (2014), 109–113.
54. 54 Pylayeva-Gupta, Y., Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 (2012), 836–847.
55. 55 Liu, Y., et al. CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis. Oncoimmunology, 5, 2015, e1061175.
56. 56 Finisguerra, V., et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522 (2015), 349–353.
57. 57 Blaisdell, A., et al. Neutrophils oppose uterine epithelial carcinogenesis via debridement of hypoxic tumor cells. Cancer Cell 28 (2015), 785–799.
58. 58 Granot, Z., et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20 (2011), 300–314.
59. 59 Srivastava, M.K., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One, 7, 2012, e40677.
60. 60 Keane, M.P., et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 172 (2004), 2853–2860.
61. 61 Mestas, J., Hughes, C.C., Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004), 2731–2738.
62. 62 Seok, J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3507–3512.
63. 63 Beura, L.K., et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532 (2016), 512–516.
64. 64 Zschaler, J., et al. Differences in innate immune response between man and mouse. Crit. Rev. Immunol. 34 (2014), 433–454.
65. 65 Zollner, O., et al. L-selectin from human, but not from mouse neutrophils binds directly to E-selectin. J. Cell Biol. 136 (1997), 707–716.
66. 66 Hajjar, E., et al. Structures of human proteinase 3 and neutrophil elastase – so similar yet so different. FEBS J. 277 (2010), 2238–2254.
67. 3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (2005), 1432–1440.
68. 68 Aleyd, E., et al. The era of the immunoglobulin A Fc receptor FcalphaRI; its function and potential as target in disease. Immunol. Rev. 268 (2015), 123–138.
69. 69 Otten, M.A., et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol. 174 (2005), 5472–5480.
70. 70 Ganz, T., Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3 (2003), 710–720.
71. 71 Rausch, P.G., Moore, T.G., Granule enzymes of polymorphonuclear neutrophils: a phylogenetic comparison. Blood 46 (1975), 913–919.
72. 72 Tamassia, N., et al. Cutting edge: an inactive chromatin configuration at the IL-10 locus in human neutrophils. J. Immunol. 190 (2013), 1921–1925.
73. 73 Tecchio, C., et al. Neutrophil-derived cytokines: facts beyond expression. Front. Immunol., 5, 2014, 508.
74. 74 Bagaitkar, J., et al. Activation of neutrophil respiratory burst by fungal particles requires phosphatidylinositol 3-phosphate binding to p40(phox) in humans but not in mice. Blood 120 (2012), 3385–3387.
75. 75 Olson, T.S., Ley, K., Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002), R7–R28.
76. 76 Dumonde, D.C., et al. Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer. J. Pathol. 138 (1982), 289–308.
77. 77 Munder, M., et al. Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105 (2005), 2549–2556.
78. 78 Dumitru, C.A., et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61 (2012), 1155–1167.
79. 79 Trellakis, S., et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int. J. Cancer 129 (2011), 2183–2193.
80. 80 Li, Y.W., et al. Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54 (2011), 497–505.
81. 81 Gentles, A.J., et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21 (2015), 938–945.
82. 82 Caruso, R.A., et al. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod. Pathol. 15 (2002), 831–837.
83. 83 Rao, H.L., et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One, 7, 2012, e30806.
84. 84 Daster, S., et al. Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. Oncoimmunology, 4, 2015, e1050574.
85. 85 Eruslanov, E.B., et al. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J. Clin. Invest. 124 (2014), 5466–5480.
86. 86 Singhal, S., et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. Cancer Cell 30 (2016), 120–135.
87. 87 Granot, Z., Fridlender, Z.G., Plasticity beyond cancer cells and the immunosuppressive switch. Cancer Res. 75 (2015), 4441–4445.
88. 88 Quatromoni, J.G., et al. An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells. J. Leukoc. Biol. 97 (2015), 201–209.
89. 89 Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
90. 90 Radsak, M., et al. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 101 (2000), 521–530.
91. 91 Potter, N.S., Harding, C.V., Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J. Immunol. 167 (2001), 2538–2546.
92. 92 Schmielau, J., Finn, O.J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61 (2001), 4756–4760.
93. 93 Rodriguez, P.C., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69 (2009), 1553–1560.
94. 94 Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
95. 95 Musiani, P., et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab. Invest. 74 (1996), 146–157.
96. 96 Colombo, M.P., et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173 (1991), 889–897.
97. 97 Mishalian, I., et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol. Immunother. 62 (2013), 1745–1756.
98. 98 Lentzsch, S., et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101 (2003), 3568–3573.